Explore
Trendline
Ionis Pharmaceuticals Announces 2026 Virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals Announces 2026 Virtual Annual Meeting of Stockholders
Read More
Trendline
INOVIO to Announce Q1 2026 Financial Results with Live Webcast
INOVIO to Announce Q1 2026 Financial Results with Live Webcast
Read More
Trendline
Kessler Topaz Meltzer Check, LLP Alerts ImmunityBio Investors of Securities Fraud Class Action
Kessler Topaz Meltzer Check, LLP Alerts ImmunityBio Investors of Securities Fraud Class Action
Read More
Trendline
Schrödinger to Engage Investors at Upcoming Healthcare Conferences
Schrödinger to Engage Investors at Upcoming Healthcare Conferences
Read More
Trendline
Modine to Participate in Oppenheimer Virtual Conference Highlighting Industrial Growth
Modine to Participate in Oppenheimer Virtual Conference Highlighting Industrial Growth
Read More
Trendline
Rosen Law Firm Urges Aldeyra Therapeutics Investors to Join Securities Class Action
Rosen Law Firm Urges Aldeyra Therapeutics Investors to Join Securities Class Action
Read More
Trendline
ImmunityBio Faces Securities Fraud Lawsuit Over Misleading Cancer Drug Claims
ImmunityBio Faces Securities Fraud Lawsuit Over Misleading Cancer Drug Claims
Read More
Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Read More
Trendline
Ionis Pharmaceuticals to Participate in Major Healthcare Investor Conferences
Ionis Pharmaceuticals to Participate in Major Healthcare Investor Conferences
Read More
Trendline
Acadia Pharmaceuticals Announces Retirement of R Head Elizabeth H.Z. Thompson, Ensuring Continuity in Alzheimer's Research
Acadia Pharmaceuticals Announces Retirement of R Head Elizabeth H.Z. Thompson, Ensuring Continuity in Alzheimer's Research
Read More
Trendline
Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments
Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments
Read More
Trendline
Eli Lilly's Stock Rises Following Strong Q1 Results and Raised Guidance
Eli Lilly's Stock Rises Following Strong Q1 Results and Raised Guidance
Read More